Current Situation
Trials are underway but questions remain about potential savings given tough issues such as patient adherence, co-morbidity, and government pricing
Goals and Objectives
Risk sharing between pharma and payers should reward drugs that demonstrate superior patient outcomes while penalizing ineffective therapies
Technology Deployed
Cloud, IoT, analytics, next-generation security, mobile
Use Case Summary
Increased transparency into RWE and patient experience will lead to reimbursement models based on value and outcomes, not marketing